Our work is funded essentially from the NHMRC, ARC and some industry partners.

  • 2017-2020. NHMRC CDF2. Modulating skin regenerative responses to improve wound repair and fight carcinogenesis. $470,144. Khosrotehrani.
  • 2020-2021: PR190852 US Department of Defense: Molecular Targets in Endovascular Progenitors to Inhibit Lung and Skin Fibrosis in Scleroderma. AU$278000 (Exact amount in negotiation). Khosrotehrani, Thomas, Talekar.
  • 2019-2021: APP1163986 NHMRC Project grant: Targeting the pre-metastatic vascular niche in melanoma using a novel molecular strategy. AU$843,856.80. Khosrotehrani, Francois, Barbour, Patel.
  • 2019-2021: DP190103187 ARC Discovery. Potency and activity of Meso-Endothelial bipotent progenitors in vivo. $350,000 Khosrotehrani, Patel, Yoder.
  • 2018-2021: APP1145350 NHMRC Project grant. Fighting epidermal skin cancers by targeting epidermal clones that accumulate mutations. $1,149,373.20. Khosrotehrani, Soyer, Saunders, Fink, Roy.